Diabetes Surgery

 

Bariatric surgery

Metabolic surgery

Purpose

Weight loss

Glycaemic/metabolic control; CV risk reduction

Indication criteria

BMI centric

Uncontrolled type 2 diabetes, metabolic syndrome, NASH, Increased CV risk

Operations

Traditional (RYGB, SG, BPD, LAGB)

Traditional (RYGB, SG, BPD, LAGB)

Investigational (DJB, IT endoscopic duodenal sleeve)

Measures of outcome

Weight loss (excess weight loss)

Glycaemic control, blood pressure, lipid control, CV risk reduction, weight loss

Presumed mechanisms of action

Restriction to food intake/malabsorption

Several, complex, neuroendocrine


Modified from Rubino and Cummings [92]

RYGB Roux-en-Y gastric bypass, SG sleeve gastrectomy, BPD biliopancreatic diversion, LAGB laparoscopic adjustable gastric banding, DJB duodenal jejunal bypass, IT ileal interposition





9.6 Diabetes Surgery: Current Priorities and Future Directions


The development of proper diabetes surgery implies a number of transformative changes to the model of care of traditional bariatric surgery. Traditional bariatric surgery practice in fact does not include accurate diagnostics measures of diabetes, evaluation of residual pancreatic function or careful screening for micro- and macrovascular complications of diabetes. Fasting insulin levels are not a mandatory routine test in most centers of excellence for bariatric surgery. This traditional practice is largely responsible for our current inability to accurately predict outcomes of bariatric surgery on diabetes based on preoperative patients’ characteristics.

Appropriate therapeutic strategies should also be developed to optimize diabetes and metabolic control. For instance, preoperative medical/dietary interventions should be considered when appropriate to improve preoperative glycaemic control. Protocols for continuation of medical therapy after surgery should be tailored to complement mechanisms of action of specific operations, introducing the concept of “adjuvant” medical therapy after surgical or device-based gastrointestinal interventions.

Finally, development of appropriate disease-based criteria for selection of surgical candidates rather than mere “weight-centric” criteria should be implemented, including measures of risks-stratification, predicting factors of success and failure, lack of responsiveness to medical and lifestyle interventions.


9.7 Conclusion


The novel field of diabetes surgery has emerged from a surgical discipline initially focused primarily on weight loss. Surgery offers a unique opportunity for remission or improved control of type 2 diabetes and could potentiate traditional therapy by lifestyle and pharmaceutical interventions. It is envisaged that ongoing RCTs and future studies will help identify the best candidates for surgical treatment among the vast population of diabetic patients, including the less obese. Furthermore, mechanistic studies aimed at using gastrointestinal surgery to elucidate the role of the gut in glucose homeostasis may possibly uncover new targets and molecules for future less invasive therapeutic approaches of curative intent.


References



1.

Rubino F, Marescaux J. The effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):1–11.PubMedCentralPubMedCrossRef


2.

Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg. 2002;236(5):554–9.PubMedCentralPubMedCrossRef


3.

Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150(6):2518–25.PubMedCrossRef


4.

Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, le Roux CW. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology. 2012;153:3613–9.PubMedCentralPubMedCrossRef


5.

Liou AP, Paziuk M, Luevano Jr JM, Machineni S, Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013;5(178):178ra41.PubMedCentralPubMed


6.

Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GW, Lam TK. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18:950–5.PubMedCrossRef


7.

Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML, Stylopoulos N. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science. 2013;341(6144):406–10.PubMedCentralPubMedCrossRef


8.

Troy S, Soty M, Ribeiro L, Laval L, Migrenne S, Fioramonti X, Pillot B, Fauveau V, Aubert R, Viollet B, Foretz M, Leclerc J, Duchampt A, Zitoun C, Thorens B, Magnan C, Mithieux G, Andreelli F. Intestinal gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice. Cell Metab. 2008;8:201–11.PubMedCrossRef


9.

Jiao J, Bae EJ, Bandyopadhyay G, Oliver J, Marathe C, Chen M, Hsu JY, Chen Y, Tian H, Olefsky JM, Saberi M. Restoration of euglycemia after duodenal bypass surgery is reliant on central and peripheral inputs in Zucker fa/fa rats. Diabetes. 2013;62(4):1074–83. doi:10.​2337/​db12-068.PubMedCentralPubMedCrossRef


10.

Dixon JB, O’Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.PubMed


11.

Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.PubMedCrossRef


12.

Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–76.PubMedCentralPubMedCrossRef


13.

Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240–9.PubMedCentralPubMedCrossRef


14.

Dixon JB, Zimmet P, Alberti KG, Rubino F, on behalf of the International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011;28(6):628–42.PubMedCentralPubMedCrossRef


15.

Rubino F, Shukla A, Pomp A, Moreira M, Ahn SM, Dakin G. Bariatric, metabolic and diabetes surgery: what’s in a name? Ann Surg. 2014;259:117–22.PubMedCrossRef


16.

Leyton O. Diabetes and operation. A note on the effect of gastro-jejunostomy upon a case of mild diabetes mellitus with a low renal threshold. Lancet. 1925;206(5336):1162–3.CrossRef


17.

Friedman MN, Sancetta AJ, Magovern GJ. The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet. 1955;100(2):201–4.PubMed


18.

Angervall L, Dotevall G, Tillander H. Amelioration of diabetes mellitus following gastric resection. Acta Med Scand. 1961;169:743–8.PubMedCrossRef


19.

Ahmad U, Danowski TS, Nolan S, Stephan T, Sunder JH, Bahl VK. Remissions of diabetes mellitus after weight reduction by jejunoileal bypass. Diabetes Care. 1978;1(3):158–65.PubMedCrossRef


20.

Printen KJ, Blommers TJ, Scott D. The morbidly obese diabetic and gastric bypass. Am Surg. 1979;45(8):491–4.PubMed


21.

Ackerman NB. Observations on the improvements in carbohydrate metabolism in diabetic and other morbidly obese patients after jejunoileal bypass. Surg Gynecol Obstet. 1981;152(5):581–6.PubMed


22.

Pories WJ, Caro JF, Flickinger EG, Meelheim HD, Swanson MS. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg. 1987;206(3):316–23.PubMedCentralPubMedCrossRef


23.

Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, de Ramon RA, Israel G, Dolezal JM. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50; discussion 350–2.PubMedCentralPubMedCrossRef


24.

Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A. Biliopancreatic diversion. World J Surg. 1998;22(9):936–46.PubMedCrossRef


25.

Cohen RV, Schiavon CA, Pinheiro JS, Correa JL, Rubino F. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22-34 kg/m2. Surg Obes Relat Dis. 2007;3:195–7.PubMedCrossRef

Mar 31, 2016 | Posted by in General Surgery | Comments Off on Diabetes Surgery
Premium Wordpress Themes by UFO Themes